期刊文献+

血清glypican 3 ELISA检测法的建立及初步应用 被引量:8

Establishment of antibody-sandwich ELISA for detection of serum glypican 3 and its clinical application
下载PDF
导出
摘要 目的建立血清中磷酯酰肌醇蛋白聚糖3(glypican 3,GPC3)的双抗体夹心ELISA检测法,并探讨其应用价值。方法以本室自制抗GPC3单克隆抗体为包被抗体,以兔抗人GPC3抗体为检测抗体,建立检测GPC3的双抗体夹心ELISA法。对建立的方法进行线性范围、灵敏度、精密度、回收率等方法学评价,并用于测定原发性肝癌、肝炎后肝硬化、慢性肝炎患者及体检健康者血清标本。结果该法线性范围为0.2~12.5μg/L,灵敏度为0.101μg/L,批内CV≤5.99%,批间CV≤6.96%,平均回收率为99.9%。原发性肝癌患者血清GPC3浓度5.43(2.28~8.62)μg/L明显高于肝炎后肝硬化、慢性肝炎患者及健康对照组(P均<0.05)。以3.19μg/L为临界值时,诊断肝癌的敏感性和特异性分别为85.4%及98.9%。结论该法灵敏、特异和准确,可用于原发性肝癌的诊断。 Objective To establish an antibody-sandwich ELISA method for detection serum glypican 3(GPC3).Methods The monoclonal and polyclonal antibody to GPC3 were prepared by ourselves,and a double-antibody-sandwich ELISA method for the detection of serum GPC3 was established.Results The linearity was from 0.2 to 12.5 μg/L.The lowest limit was 0.101 μg/L.The coefficients of variation(CV) of within-run and between-run were less than 5.99% and 6.96% respectively,and the average recovery was 99.9%.Clinical studies showed that the concentration of GPC3 in the sera of patients with primary hepatocarcinoma was 5.43(2.28-8.62) μg/L,which was significantly higher than that in benign liver diseases(P0.05).When cut-off value was 3.19 μg/L,the sensitivity and specificity of primary hepatocarcinoma diagnosis was 85.4% and 98.9% respectively.Conclusion The established ELISA is sensitive,specific and accurate in this study.The detection of serum GPC3 should be helpful for the diagnosis of primary hepatocarcinoma.
出处 《临床检验杂志》 CAS CSCD 北大核心 2011年第4期244-246,共3页 Chinese Journal of Clinical Laboratory Science
基金 南通市社会发展计划项目(S7943)
关键词 磷脂酰肌醇蛋白聚糖3 ELISA法 原发性肝癌 glypican 3 enzyme-linked immunosorbent assay primary hepatocarcinoma
  • 相关文献

参考文献6

二级参考文献21

  • 1Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker[J]. Gastroenterology, 2004, 127(2):679-680.
  • 2Mast AE, Higuchi AD, Huang ZF. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor[J]. Biochemj, 1997,327(Pt2):557-578.
  • 3Cumberledge S, Reichsman F. Glycosam inoglycans and WNTs just a spoonful of sugar helps the signal go down[J]. Trends Genet,1997,13(11):421-423.
  • 4Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical wnt signaling[J]. Cancer Res, 2005,65(14):6245-6254.
  • 5Kwack MH, Choi BY, Sung YK. Cellular changes resuhing from forced expression of glypican-3 in hepatocellular carcinoma cells[J]. Mol Cells, 2006,21(2):224-228.
  • 6Sung YK, Hwang SY, Park MK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma[J]. Cancer Sci, 2003,94(3):259-262.
  • 7Yamanaka K, Ito Y, Okuyama N. Immunohistochemical study of glypican 3 in thyroid cancer[ J ]. Oncology ,2007,73 (545) :389-394.
  • 8Nishimura Y, Nakatsura T, Senju S. Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma[ J]. Nihon Rinsho Meneki Gakkai Kaishi, 2008,31 (5) :383-391.
  • 9Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer [ J ]. Cell Cycle, 2008,7 ( 18 ) :2787-2790.
  • 10Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early stage hepatocellular carcinoma [ J ]. Cancer Res ,2004 ,64 :2418-2423.

共引文献1916

同被引文献71

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部